Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1850-1859

  Anger, Gregory J ^a   Piquette Miller, Micheline ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A2; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; FETUS; LIQUID CHROMATOGRAPHY; LIVER; LIVER CLEARANCE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PREGNANCY DIABETES MELLITUS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRACENTRIFUGATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DIABETES, GESTATIONAL; FEMALE; FETUS; HIV PROTEASE INHIBITORS; LIVER; LOPINAVIR; MATERNAL-FETAL EXCHANGE; MEMBRANE PROTEINS; P-GLYCOPROTEIN; PLACENTA; PREGNANCY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, STEROID; UP-REGULATION;

RATTUS; RODENTIA;

EID: 80053168636     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040626     Document Type: Article

References (45)

1. Abbott Laboratories Ltd. (2010) Kaletra (product monograph). Abbott Laboratories Ltd., Saint- Laurent, Quebec, Canada.
2. Agarwal S, Pal D, and Mitra AK (2007) Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339:139-147. (Pubitemid 46977600)
3. Anger GJ, Magomedova L, and Piquette-Miller M (2009) Impact of acute streptozotocin-induced diabetes on ABC transporter expression in rats. Chem Biodivers 6:1943-1959.
4. Anger GJ and Piquette-Miller M (2010) Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes. J Pharmacol Exp Ther 334:21-32.
5. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV, et al. (2010) Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 11:232-238.
6. Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, and Di Perri G (2002) Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 16:2081-2083. (Pubitemid 35205274)
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Ceccaldi PF, Mandelbrot L, Ferreira C, Farinotti R, Forestier F, and Gil S (2010) Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide. Retrovirology 7:P164.
9. Chandra P and Brouwer KL (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21:719-735. (Pubitemid 39011292)
10. Chappuy H, Tréluyer JM, Rey E, Dimet J, Fouché M, Firtion G, Pons G, and Mandelbrot L (2004) Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 191:558-562. (Pubitemid 39178714)
11. Choi JS and Burm JP (2008) Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Arch Pharm Res 31:1200-1204.
12. Gahir SS and Piquette-Miller M (2011) Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice. Drug Metab Dispos 39:465-471.
13. Gavard L, Gil S, Peytavin G, Ceccaldi PF, Ferreira C, Farinotti R, and Mandelbrot L (2006) Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol 195:296-301. (Pubitemid 43927527)
14. González-Tomé MI, Ramos Amador JT, Guillen S, Solís I, Fernández-Ibieta M, Muñoz E, Almeda J, Rojano X, Rojo P, Nieto O, et al. (2008) Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 9:868-874.
15. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
16. Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, Calligaris F, Abraham B, Pialoux G, Girard PM, et al. (2003) High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47:986-990. (Pubitemid 36258358)
17. Gwilt PR, Nahhas RR, and Tracewell WG (1991) The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 20:477-490.
18. Hanada K, Ikemi Y, Kukita K, Mihara K, and Ogata H (2008) Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats. Drug Metab Dispos 36:2037-2042.
19. Handschin C and Meyer UA (2005) Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433:387-396. (Pubitemid 39592793)
20. Hasegawa Y, Kishimoto S, Shibatani N, Inotsume N, Takeuchi Y, and Fukushima S (2010) Effects of insulin on CYP3A activity and nicardipine disposition in streptozotocin-induced diabetic rats. J Pharm Pharmacol 62:883-889.
21. Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, and Wakusawa S (2008) Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim Biophys Acta 1782:355-360.
22. Kis O, Robillard K, Chan GN, and Bendayan R (2010) The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22-35.
23. Kourtis AP, Bansil P, McPheeters M, Meikle SF, Posner SF, and Jamieson DJ (2006) Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994-2003. AIDS 20:1823-1831. (Pubitemid 44358900)
24. Kumar GN, Jayanti VK, Johnson MK, Uchic J, Thomas S, Lee RD, Grabowski BA, Sham HL, Kempf DJ, Denissen JF, et al. (2004) Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 21:1622-1630. (Pubitemid 41184393)
25. Lee JH, Yang SH, Oh JM, and Lee MG (2010) Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 62:1-23.
26. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023. (Pubitemid 28419246)
27. Maeng HJ, Kim MH, Jin HE, Shin SM, Tsuruo T, Kim SG, Kim DD, Shim CK, and Chung SJ (2007) Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocininduced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos 35:1996-2005. (Pubitemid 350005189)
28. Martí C, Peña JM, Bates I, Madero R, De José I, Pallardo LF, Arribas JR, Gonzalez-Garcia J, Gonzalez A, and Vazquez JJ (2007) Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003. Acta Obstet Gynecol Scand 86:409-415. (Pubitemid 46747713)
29. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H, et al. (2002) Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 46:2926-2932.
30. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, and Stieger B (2006) Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44:62-74. (Pubitemid 44049139)
31. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, and Sullivan JL (2002) Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 21:835-838.
32. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216. (Pubitemid 351185732)
33. Mulay S and Varma DR (1984) Influence of streptozotocin-diabetes on the pharmacokinetics, placental transfer and tissue localization of dexamethasone in rats. Br J Pharmacol 83:139-144. (Pubitemid 14028824)
34. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, and Gotoh O (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51. (Pubitemid 23064489)
35. Petrovic V, Wang JH, and Piquette-Miller M (2008) Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats. Drug Metab Dispos 36:1944-1950.
36. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, et al. (2006) Reduced lopinavir exposure during pregnancy. AIDS 20:1931-1939. (Pubitemid 44427610)
37. Tirona RG (2011) Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol 201:373-402.
38. Tracy TS, Korzekwa KR, Gonzalez FJ, and Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47:545-552. (Pubitemid 29199727)
39. Van Waterschoot RA, ter Heine R, Wagenaar E, Van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, and Schinkel AH (2010) Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160:1224-1233.
40. Wang JH, Scollard DA, Teng S, Reilly RM, and Piquette-Miller M (2005) Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J Nucl Med 46: 1537-1545. (Pubitemid 46173265)
41. Wang PG, Wei JS, Kim G, Chang M, and El-Shourbagy T (2006) Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction. J Chromatogr A 1130:302-307. (Pubitemid 44441317)
42. Watts DH, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, Newell ML, Delfraissy JF, Gelber RD, Mofenson LM, et al. (2004) Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 190:506-516. (Pubitemid 38249253)
43. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761. (Pubitemid 36617664)
44. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, and Novack L (2009) Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 201:482.e1-482.e8.
45. Woodahl EL, Yang Z, Bui T, Shen DD, and Ho RJ (2005) MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19:1617-1625. (Pubitemid 41502674)